New developments and treatment in multiple myeloma: new insights on molecular biology.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Annals of Oncology

• Publication date

  2002-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDF637PMID 12401665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

  2002cited by this paper
• The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.

  2001cited by this paper
• Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy

  2001cited by this paper
• Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

  2001cited by this paper
• Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique.

  2001cited by this paper
• Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis.

  2001cited by this paper
• Hypodiploidy is a major prognostic factor in multiple myeloma.

  2001cited by this paper
• Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.

  2001cited by this paper
• Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma

  2001cited by this paper
• Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

  2001cited by this paper
• The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells.

  2001cited by this paper
• Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

  2001cited by this paper
• Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.

  2001influential reference
• Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.

  2001cited by this paper
• Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.

  2000cited by this paper
• SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.

  2000cited by this paper
• Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization

  2000cited by this paper
• The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies.

  2000cited by this paper
• Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)

  2000cited by this paper
• Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

  2000cited by this paper
• Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance

  2000cited by this paper
• Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

  2000cited by this paper
• Prognostic value of bone marrow angiogenesis in multiple myeloma.

  2000cited by this paper
• Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.

  2000cited by this paper
• Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).

  2000cited by this paper
• Molecular analysis of 11q13 breakpoints in multiple myeloma.

  1999cited by this paper
• Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.

  1999cited by this paper
• Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.

  1999cited by this paper
• Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.

  1999cited by this paper
• 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.

  1999cited by this paper
• Identification of New Nonrandom Translocations in Multiple Myeloma With Multicolor Spectral Karyotyping

  1998cited by this paper
• Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.

  1998cited by this paper
• Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes.

  1998cited by this paper
• Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.

  1998cited by this paper
• Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases

  1998cited by this paper
• High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.

  1998cited by this paper
• Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.

  1998cited by this paper
• Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma

  1997cited by this paper
• Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

  1997cited by this paper
• A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.

  1997cited by this paper
• Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.

  1997cited by this paper
• Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.

  1996cited by this paper
• MULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMAL

  1996cited by this paper
• The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4.

  1996cited by this paper
• Promiscuous translocations into igh switch regions: The genetic hallmark of multiple myeloma

  1996cited by this paper
• Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

  1996cited by this paper
• Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance.

  1995cited by this paper
• Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma.

  1995cited by this paper
• Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6.

  1995cited by this paper
• Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells

  1995cited by this paper
• p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy.

  1993cited by this paper
• R E V I E W a Rt I C L E

  year unknowninfluential reference
• CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Monosomy 13 Is Associated With the Transition of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

  year unknowncited by this paper

• Autologous Bone Marrow Transplant in Multiple Myeloma Patient With Bone Marrow Hematopoietic Stem Cell.

  2020cites this paper
• Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma

  2018cites this paper
• Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells

  2017cites this paper
• Extranodal Marginal Zone Lymphoma

  2017cites this paper
• Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract.

  2010cites this paper
• Quand faire de la chimiothérapie néoadjuvante? Ľutilisation de la chimiothérapie néoadjuvante chez des patientes atteintes de cancer du sein opérable (stades II et III)

  2007cites this paper
• The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.

  2007cites this paper
• Chimiothérapie néo-adjuvante. Expérience du centre Jean-Perrin. Importance de la tumeur résiduelle et de la rémission histologique complète

  2006cites this paper
• Potential role of ABC transporters as a detoxification system at the blood-CSF barrier.

  2004cites this paper
• Potential role of ABC transporters as a detoxification system at the blood-CSF barrier.

  2004cites this paper
• Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells.

  2004cites this paper
• Gene therapy for hematological malignancies

  2003cites this paper